EFFECTS OF SYSTEMIC INTERFERON-ALPHA (IFN-ALPHA) ON THE ANTIGENIC PHENOTYPE OF MELANOMA METASTASES - EORTC MELANOMA GROUP COOPERATIVE STUDY NO-18852

被引：28

作者：

VONSTAMM, U ^{[1
]}

BROCKER, EB ^{[1
]}

PRONDZINSKI, MV ^{[1
]}

RUITER, DJ ^{[1
]}

RUMKE, P ^{[1
]}

BRODING, C ^{[1
]}

CARREL, S ^{[1
]}

LEJEUNE, FJ ^{[1
]}

机构：

[1] UNIV MUNSTER,DEPT DERMATOL,W-4400 MUNSTER,GERMANY

来源：

MELANOMA RESEARCH | 1993年 / 3卷 / 03期

关键词：

ICAM-1; INTERFERON-ALPHA; MELANOMA ANTIGENS; METASTATIC MELANOMA; MHC ANTIGENS; PIGMENTATION; PROLIFERATION;

D O I：

10.1097/00008390-199306000-00005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In order to investigate the effects of in vivo treatment with interferon-alpha (IFN-alpha) on melanoma antigens, a clinical EORTC trial (No. 18852) was accompanied by an immunohistological study. Twenty patients with melanoma metastases of skin and soft tissues, eventually also of the lung, who were treated with systemic IFN-alpha, were evaluated for a comparison of metastases before (40) and during (42) treatment. Representative cryostat sections were studied immunohistologically with a panel of monoclonal antibodies against differentiation antigens (HMW-MAA, K-1-2, NKI-beteb, M-2-10-15), progression markers (transferrin receptor, ICAM-1, VLA-2), histocompatiblilty antigens (HLA-A, B, C, HLA-DR) and the proliferation-associated nuclear antigen Ki67. We found an overall reduction of the proliferation-associated antigen Ki-67 (p < 0.01), and an increase in expression of HLA-DR (p < 0.05) and ICAM-1 (trend) during treatment. The intensity of expression of HLA-A, B and C antigens as well as pigmentation (p < 0.01) was found to be increased. Early progression (less-than-or-equal-to 8 weeks after onset of treatment) was associated with a lack of phenotypic changes. The data suggest an independent modulation of proliferation, pigmentation, and antigen expression by systemic treatment of metastatic melanoma with IFN-alpha.

引用

页码：173 / 180

页数：8

共 50 条

[1]

Carrel S., Schmidt-Kessen A., Giuffre L., Recombinant inter-feron-gamma can induce the expression of HLA-DR and-DC on -DR negative melanoma cells and enhance the expression of HLA-ABC and tumour associated antigens, Eur J Immunol, 15, pp. 118-123, (1985)

[2]

Giacomini P., Fischer P.B., Duigou G.J., EI al. Regulation of class II MHC gene expression by interferons

[3]

insights into the mechanism of action of interferon, Anticancer Res, 8, pp. 1153-1161, (1988)

[4]

Giacomini P., Fraioli R., Nistico P., El al. Modulation of the antigenic phenotype of carly-passagc human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon, Int J Cancer, 46, pp. 539-545, (1990)

[5]

Maio M., Gulwani B., I.Agncr)A, el al. Modulation by interferons of HLA antigen, high-molecular-weight melanoma-associated antigen, and intercellular adhesion molecule 1 expression bv cultured melanoma cells with different metastatic potential, Cancer Res, 49, pp. 2980-2987, (1989)

[6]

Nistico P., Teccc R., Giacomini P., El al. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells, Cancer Res, 50, pp. 7422-7429, (1990)

[7]

McMichael A.J., Tuig A., Zweernik H.J., El al. HLA restriction of cell mediated lysis of influenza virus-infected human cells, Nature, 270, pp. 524-526, (1977)

[8]

Hersey P., McDonald M., Hall C., Immunological effects of recombinant interferon alpha 2a in patients with disseminated melanoma, Cancer, 57, pp. 1666-1674, (1986)

[9]

McLeod G.R., Thomson D.B., Hersey P., Clinical evaluation of interferons in malignant melanoma, J Invest Dermatol, 95, pp. 185-187, (1990)

[10]

Creagan E.T., Schaid D.J., Ahmann D.L., Disseminated malignant melanoma and recombinant interferon: Analysis of seven consecutive phase II investigations, J Invest Dermatol, 95, pp. 188-192, (1990)

← 1 2 3 4 5 →